Agenus Inc - A Potential New Play On Ebola

Shares of Agenus Inc (NASDAQ: AGEN) have moved to the upside in Monday's trade as the company is being mentioned as a potential play on Ebola.

In 2011, the company announced a license agreement with Integrated BioTherapeutics Inc. for the use of the QS-21 Stimulon adjuvant in the development of a vaccine against Ebola and Marburg viruses.

According to Agenus, QS-21 Stimulon adjuvant strengthens and broadens immune responses to a vaccine's antigen, facilitating its ability to target invading organisms or diseased cells.

Shares of Agenus were last up 5.4 percent at $2.75.